Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SDHB | P21912 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734115 | 0.86 | NPSR1 (0.44) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL2816888 | 0.82 | HSP90AA1 (0.52) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL1734114 | 0.79 | BPTF (0.57) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL1733692 | 0.79 | ADORA3 (0.49) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL1734398 | 0.79 | CHRNA7 (0.49) | HPGDKDM4ECHRNA7KMT2AADORA3 | |
| SCHEMBL1733437 | 0.77 | ADORA3 (0.44) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL19805677 | 0.76 | NPSR1 (1.00) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL1734511 | 0.76 | KDM4E (0.66) | HPGDKDM4ECHRNA7ADORA3HSP90AA1 | |
| SCHEMBL1734400 | 0.74 | LMNA (0.45) | HPGDLMNANPSR1KDM4EHTT | |
| SCHEMBL30755408 | 0.74 | ALDH1A1 (0.61) | HPGDLMNAKDM4EHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| EP-1891018-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131686-A1 | A THERMALLY CONTROLLED ASSEMBLY | NAPATECH A/S (DK) | 2011-10-27 | — | — | WO | disclosed |
| EP-1891018-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| WO-2006127588-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | ABCC4, CFTR, ABCC2 | HPGD 1462/4885LMNA 3617/4885NPSR1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.